Form 4: Director William Chang Acquires Semler Scientific Stock Options

Semler Scientific Director William H. Chang was granted 4,000 stock options with an exercise price of $17.78, exercisable immediately.

Summary

• William H. Chang, a Director of Semler Scientific, Inc. (SMLR), acquired 4,000 stock options.
• The options have an exercise price of $17.78 per share.
• The grant date and exercisable date for these options is January 2, 2026.
• The options expire on January 2, 2036.
• Following this transaction, Mr. Chang directly beneficially owns 4,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director, exercisable at $17.78, indicates a potential alignment of interests with future stock price appreciation. It's a common compensation practice and suggests management's belief in future growth.

Positives

• A director acquiring stock options can signal confidence in the company's future performance.
• The options are immediately exercisable, providing flexibility for the director.

Negatives

• No immediate cash investment by the director, as the options were granted rather than purchased.

Risks

• The value of the options is dependent on the future stock price exceeding the exercise price of $17.78.
• Market volatility could impact the profitability of these options.

Future Outlook

The acquisition of stock options by a director suggests an expectation of future stock price appreciation, as the options only become valuable if the stock price rises above the exercise price.

Industry Context

This is an insider transaction, which is common across all industries as part of executive and director compensation packages. It does not directly relate to broader industry trends beyond general market sentiment affecting option value.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in corporate compensation across various industries, aligning director interests with shareholder value.
• The specific exercise price of $17.78 would need to be compared to the company's stock price on the grant date (01/02/2026) to assess if it was granted 'at-the-money,' 'in-the-money,' or 'out-of-the-money' relative to the market price at that time.

Related Party Transactions

• This transaction represents a standard related party dealing as part of director compensation.

Stakeholder Impact

• Shareholders: Potential positive signal of director confidence; however, future exercise of options could lead to share dilution.
• Management/Employees: This reflects a standard compensation practice for directors.

Next Steps

• The director will hold these options and may choose to exercise them at any point between the exercisable date and the expiration date, provided the stock price is above the exercise price.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their compensation. While it signals some insider confidence, it does not involve a direct cash purchase of shares and is unlikely to be a standalone catalyst for a 'buy' or 'sell' recommendation. It's a standard corporate governance event.

Keywords

Semler Scientific, SMLR, Stock Options, Insider Trading, Form 4, Director Compensation, Equity Grant, Beneficial Ownership